At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Biological and Behavioral Mechanisms of Smoking in Schizophrenia
In Brief
A Phase 2 clinical trial evaluating sensorimotor replacement, 42 mg transdermal nicotine replacement, and 2 other interventions for Tobacco Use Disorder and Schizophrenia. Completed, enrolled 75 participants across 1 site.
Detailed Summary
The objective of this study is to investigate the relative contributions of nicotine replacement and sensorimotor replacement (i.e., smoking denicotinized cigarettes) on abstinence-induced smoking urges, withdrawal-related negative affect, psychiatric symptoms, cognitive task performance and 90-min ad libitum usual-brand smoking behavior in smokers with schizophrenia and non-psychiatric smokers.
Study Details
Timeline
Interventions
denicotinized cigarettes
2 21-mg nicotine patches
2 placebo patches matched to 21-mg nicotine patches
participant smokes usual brand of cigarette